Copper-Mediated Perfluoroalkylation of Heteroaryl Bromides with (phen)CuR<sub>F</sub>
作者:Michael G. Mormino、Patrick S. Fier、John F. Hartwig
DOI:10.1021/ol500422t
日期:2014.3.21
synthetic goal over the past several decades. Previously, our group reported phenanthroline-ligated perfluoroalkyl copperreagents, (phen)CuRF, which react with aryliodides and aryl boronates to form the corresponding benzotrifluorides. Herein the perfluoroalkylation of a series of heteroaryl bromides with (phen)CuCF3 and (phen)CuCF2CF3 is reported. The mild reaction conditions allow the process to tolerate
[EN] 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE SUBSTITUÉS PAR UN GROUPE 2-HYDROXYMÉTHYLE
申请人:MERCK SHARP & DOHME
公开号:WO2014176144A1
公开(公告)日:2014-10-30
The present invention is directed to 2-hydroxymethyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
The present invention is directed to 2-hydroxymethyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.